ENTA
NASDAQ · Biotechnology
Enanta Pharmaceuticals Inc
$13.77
+0.43 (+3.22%)
Open$13.43
Previous Close$13.34
Day High$13.87
Day Low$13.35
52W High$17.15
52W Low$6.45
Volume—
Avg Volume163.6K
Market Cap387.91M
P/E Ratio—
EPS$-2.59
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+223.5% upside
Current
$13.77
$13.77
Target
$44.55
$44.55
$33.16
$44.55 avg
$53.28
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 89.84M | 98.54M | 75.01M |
| Net Income | -112,618,796 | -111,173,539 | -19,564,680 |
| Profit Margin | -125.4% | -119.1% | -26.1% |
| EBITDA | -111,069,521 | -115,735,488 | -21,379,947 |
| Free Cash Flow | — | — | -13,998,479 |
| Rev Growth | -8.8% | -8.8% | -3.9% |
| Debt/Equity | 2.21 | 2.21 | 0.40 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |